Stuart Bryan 4
4 · Fulcrum Therapeutics, Inc. · Filed Aug 12, 2021
Insider Transaction Report
Form 4
Stuart Bryan
Chief Operating Officer
Transactions
- Sale
Common Stock
2021-08-10$17.50/sh−32,000$560,000→ 0 total - Sale
Common Stock
2021-08-11$23.75/sh−28,000$665,000→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-10−32,000→ 271,571 totalExercise: $7.84Exp: 2028-12-17→ Common Stock (32,000 underlying) - Exercise/Conversion
Common Stock
2021-08-10$7.84/sh+32,000$250,880→ 32,000 total - Exercise/Conversion
Common Stock
2021-08-11$7.84/sh+28,000$219,520→ 28,000 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-11−28,000→ 243,571 totalExercise: $7.84Exp: 2028-12-17→ Common Stock (28,000 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
- [F2]This option was granted on December 18, 2018 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of December 18, 2018. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.